Refractory psoriasis vulgaris with itching successfully treated with the anti-interleukin-17A antibody secukinumab: A case of secondary failure of other biologic agents

A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor

“…An interesting article from Kurosaki et al describes a case of refractory psoriasis and pruritus, which became unresponsive to several biologics (ustekinumab, adalimumab, infliximab plus MTX). Treatment was switched to secukinumab, and after 32 weeks, PASI 100 was achieved [12].…”